Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Sio Gene Therapies Inc
Sio Gene Therapies Inc logo

SIOX - Sio Gene Therapies Inc Share News

$2.51 -0.1  -2.0%

Last Trade - 05/03/21

Sector
Healthcare
RiskRating
Speculative
Size
Small Cap
Style
Sucker Stock
Market Cap £106.5m
Enterprise Value £42.2m
Revenue £n/a
Position in Universe 4682nd / 6651
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions SIOX Dividends
All News
All News Reuters News Company Announcements
Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference
16th Feb News
BRIEF-Sio Gene Therapies Posts Q3 Loss Per Share $0.20
9th Feb News
Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020
9th Feb News
BRIEF-Sio Gene Therapies Announces Receipt Of $11.6 Million From Closing Of The Sale Of Arvelle Therapeutics
4th Feb News
Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics
4th Feb News
BRIEF-Sio Gene Therapies Announces First Patient Dosed In Clinical Trial Of AXO-AAV-GM2 In Patients With Tay-Sachs And Sandhoff Disease
3rd Feb News
Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
3rd Feb News
BRIEF-Sio Gene Therapies To Sell Arvelle Stake As Part Of Angelini Pharma’S Acquisition Of Arvelle Therapeutics
4th Jan News
Sio Gene Therapies to Sell Arvelle Stake as Part of Angelini Pharma’s Acquisition of Arvelle Therapeutics
4th Jan News
BUZZ-U.S. STOCKS ON THE MOVE-Arvinas, BioCardia, Hexindai
16th Dec '20 News
BRIEF-Sio Gene Therapies Inc Files For Offering Of Up To $100 Million Of Common Stock - SEC Filing
16th Dec '20 News
BUZZ-Sio Gene: Surges on positive follow-up data from gene therapy study
16th Dec '20 News
BRIEF-Sio Gene Therapies Announces Positive Six-Month Follow-Up Data From Low-Dose Cohort Of Phase 1/2 Trial Of Axo-Aav-Gm1 For Gm1 Gangliosidosis
15th Dec '20 News
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
15th Dec '20 News
BUZZ-Sio Gene: Up after starting high-dose part of gene therapy study
2nd Dec '20 News
BRIEF-Sio Gene Therapies Says On-Track To Report Topline Results From Low-Dose Cohort By End Of 2020
2nd Dec '20 News
Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis
2nd Dec '20 News
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor
19th Nov '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.